INNOVATION MODELS IN THE BIOPHARMACEUTICAL SECTOR - Innovation in the Biopharmaceutical Industry - page 25

Bailey, S, J Freeman and R Hybels (1994). Strategic alliances in commercial biotechnology.
In Networks and Organisations: Structure, Form and Action , N Nohria and R Eades
(eds.). Boston: HBS Press.
Baumol WJ (2002). The Free Market Innovation Machine . Princeton University Press.
Baumol, WJ (2006). Return of the invisible men: the microeconomic value the-
ory of inventors and entrepreneurs. Paper presented at the American Economic
Association Annual Meeting, 6-8 January. Available at URL: www.aeaweb.org/
annual − mtg − papers/2006papers.html.
Berkhout, F and K Green (2003). Managing innovation for sustainability. International
Journal of Innovation Management , 6(3).
Berndt, E (2003). Comparing diffusion paths of new pharmaceuticals in Canada and the
USA. Paper Presented at iHEA 4th World Congress, San Francisco, (A) USA, 15-18
June.
Bhide, A (2006). Venturesome consumption, innovation and globalisation. CESIFO Con-
ference on “Perspectives on the Performance of the Continent's Economies, Venice,
21-22 July. Available at URL: www.bhide.net/publications.html.
Boston Consulting Group (1999). The Pharmaceutical Industry into Its Second Century:
From Serendipity to Strategy.
Bower, J (2003). Business model fashion and the academic spin out firm. R&DManagement
33(2), 97-106.
Cambridge

Pharma Consulting (2002). Delays in Market Access . Cambridge UK:

Cambridge Pharma.
Cantwell, J (1992). The internationalisation of technological activity and its implica-
tions for competitiveness. In Technology Management and International Business ,
O Granstrand, L Hakanson and S Sjolander (eds.), pp. 75-95. Chichester: John Wiley.
Charles River Associates (2004). Innovation in the Pharmaceutical Sector: A Study Under-
taken for the European Commission. Available at http: //pharmacos.eudra.org/F2/ phar-
macos/docs/Doc2004/nov.
Chesborough, H (2003). Open Innovation: The New Imperative for Creating and Profiting
form Technology . Boston, MA: Harvard Business School Press.
Comanor, WS (1986). The political economy of the pharmaceutical industry. Journal of
Economic Literature , XXIV, 1178.
Conway, S and F Steward (2006). Managing Innovation . Oxford: Oxford University Press.
Daily Telegraph (2006). Venture Capital-Don't mind the gap, “it's a perception”, Tuesday,
1 August, p. B8. Available at URL: www.telegraph.co.uk.
Danzon, PM and JD Kim (2002). The Life Cycle of Pharmaceuticals: A Cross-national
Perspective . London: Office of Health Economics Monograph (OHE).
Deeds, DL, D DeCarolis and J Coombs (2000). Dynamic capabilities and new product
development in high technology ventures: an empirical analysis of new biotechnology
firms. Journal of Business Venturing , 15(3), 211-229.
Dickenson, ML and JW Gentry (1983). Characteristics of adopters and non-adopters of
home computers. Journal of Consumer Research , 225.